title: Dronedarone in patients with atrial fibrillation.
abstract: Dronedarone is a recently developed new class III antiarrhythmic drug which possesses electrophysiological properties of all four Vaughan-Williams classes. An important difference with amiodarone is that it does not contain an iodine component and therefore lacks the iodine-related adverse effects. Based on currently available data, dronedarone can not be recommended as first-line therapy for either rhythm or rate control. We recommend to initiate rhythm or rate control with drugs as indicated in the 2006 guidelines of the ESC and other organisations. As amiodarone, dronedarone can be given to patients for whom standard drug therapy is not effective, or limited by (severe) side effects, although it is less effective than amiodarone. Nevertheless, it may be considered to give dronedarone initially to patients who would otherwise have received amiodarone, since the latter has more severe side effects than the former drug. The daily dosage of dronedarone is oral administration, 400 mg twice daily. Dronedarone is contraindicated in patients with impaired left ventricular function (NYHA class III/IV) and haemodynamic instability. (Neth Heart J 2010;18:370-3.).
authors: Department of Cardiology, Erasmus Medical Center Rotterdam, the Netherlands.
authors: N M S
authors: NM
authors: de Groot
authors: C J
authors: CJ
authors: Kirchhof
authors: I C
authors: IC
authors: van Gelder
authors: J G
authors: JG
authors: Meeder
authors: A H M M
authors: AH
authors: Balk
authors: A A
authors: AA
authors: Wilde
authors: M L
authors: ML
authors: Simoons